TickerFacts.

Neurocrine Biosciences Inc (NBIX): Share Repurchases

Annual figures by period end, from SEC filings.

$167.70M
Year ended 2025-12-31
$66.00M
Trailing 12 months to 2026-06-30
$300.00M2022-12-31: $02023-12-31: $02024-12-31: $300.00M2025-12-31: $167.70M$167.70M
2022-12-31 Share Repurchases (USD) 2025-12-31
Period endedShare RepurchasesChange YoYSource filing
2025-12-31$167.70M-44.1%2026-02-11, From 2025-01-01
2024-12-31$300.00Mn/a2026-02-11, From 2024-01-01
2023-12-31$0n/a2026-02-11, From 2023-01-01
2022-12-31$0n/a2025-02-10, From 2022-01-01

Share Repurchases at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShare RepurchasesChange YoY
Neurocrine Biosciences Inc (NBIX)2025-12-31$167.70M-44.1%
Exelixis, Inc. (EXEL)2026-01-02$947.51M+45.3%
Qiagen N.V. (QGEN)2025-12-31$280.09M-4.1%
Moderna, Inc. (MRNA)2025-12-31$2.00Mn/a
Halozyme Therapeutics, Inc. (HALO)2025-12-31$342.37M+36.9%
Bio-Techne Corp (TECH)2026-06-30$41.67M-84.9%
Biogen Inc. (BIIB)2024-12-31$0n/a
Repligen Corp (RGEN)2025-12-31$0n/a
ADMA Biologics, Inc. (ADMA)2025-12-31$31.94Mn/a

Compare NBIX, EXEL, QGEN, MRNA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗